News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Weather
E-Edition
Subscribe
Sign Up For Newsletters
News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Equillium, Inc.
< Previous
1
2
Next >
Equillium Announces Initiation of Phase 2 study of EQ101 A First-in-Class Multi-Cytokine Inhibitor of IL-2, IL-9 and IL-15 Targeting Alopecia Areata
November 10, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at Two Upcoming Investor Conferences
November 08, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Presentation at the 6th Annual Dermatology Drug Development Summit
November 03, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease
November 02, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology Conference
October 26, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis
September 27, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Abstract Accepted for Presentation at ACR Convergence 2022
September 15, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Acquire Metacrine in All-Stock Transaction
September 06, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
MTCR
Equillium to Present at Two Upcoming Investor Conferences
August 31, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development Updates
August 15, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Presentation at the 3rd Annual Cytokine-Based Drug Development Summit
July 28, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at Two Upcoming Investor Conferences
May 17, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development Updates
May 12, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Publication of Abstract for the Annual Congress of the European Hematology Association
May 12, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of Immunologists
May 09, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR
April 25, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Oral Presentation at the Italian Society of Experimental Hematology
April 04, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates
March 23, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Two Oral Presentations at the Annual Meeting of the European Society for Blood and Marrow Transplantation
March 23, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates
February 16, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Provides Timing Update on Conference Presentations
February 15, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at the SVB Leerink Virtual Global Healthcare Conference
February 09, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT and CIBMTR
January 10, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference
January 05, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Publication of Data in the Journal of Clinical Investigation Highlighting the Importance of the CD6-ALCAM Pathway in the Pathogenesis of Lupus Nephritis
January 04, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Data from Phase 1b EQUIP Study in Patients with Uncontrolled Asthma
January 04, 2022
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Announces Additional Patient Data at ASH 2021 Demonstrating Continued Positive and Durable Clinical Responses in Acute Graft-Versus-Host Disease Patients Treated with Itolizumab
December 13, 2021
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates
November 10, 2021
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium to Present at Two Upcoming Investor Conferences
November 09, 2021
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
Equillium Presents Interim Safety Data from First Cohort of Asthma Patients in Phase 1b EQUIP Study at the American College of Allergy, Asthma & Immunology Meeting
November 05, 2021
From
Equillium, Inc.
Via
Business Wire
Tickers
EQ
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close